- Home
- BDTX vs ADVM Comparison
BDTX vs ADVM Comparison
Compare BDTX & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- ADVM
- Stock Information
- Founded
- BDTX 2014
- ADVM 2006
- Country
- BDTX United States
- ADVM United States
- Employees
- BDTX N/A
- ADVM N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BDTX Health Care
- ADVM Health Care
- Exchange
- BDTX Nasdaq
- ADVM Nasdaq
- Market Cap
- BDTX 144.9M
- ADVM 119.6M
- IPO Year
- BDTX 2020
- ADVM 2014
- Fundamental
- Price
- BDTX $2.48
- ADVM $5.13
- Analyst Decision
- BDTX Strong Buy
- ADVM Strong Buy
- Analyst Count
- BDTX 4
- ADVM 6
- Target Price
- BDTX $15.50
- ADVM $27.83
- AVG Volume (30 Days)
- BDTX 476.4K
- ADVM 286.5K
- Earning Date
- BDTX 11-05-2024
- ADVM 11-04-2024
- Dividend Yield
- BDTX N/A
- ADVM N/A
- EPS Growth
- BDTX N/A
- ADVM N/A
- EPS
- BDTX N/A
- ADVM N/A
- Revenue
- BDTX N/A
- ADVM $1,000,000.00
- Revenue This Year
- BDTX N/A
- ADVM N/A
- Revenue Next Year
- BDTX N/A
- ADVM N/A
- P/E Ratio
- BDTX N/A
- ADVM N/A
- Revenue Growth
- BDTX N/A
- ADVM N/A
- 52 Week Low
- BDTX $2.31
- ADVM $4.97
- 52 Week High
- BDTX $7.66
- ADVM $29.70
- Technical
- Relative Strength Index (RSI)
- BDTX 43.96
- ADVM 31.23
- Support Level
- BDTX $2.43
- ADVM $4.97
- Resistance Level
- BDTX $2.66
- ADVM $6.07
- Average True Range (ATR)
- BDTX 0.16
- ADVM 0.35
- MACD
- BDTX 0.05
- ADVM -0.05
- Stochastic Oscillator
- BDTX 48.81
- ADVM 14.93
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.